SYNERGENE THERAPEUTICS, INC.

Address

SYNERGENE THERAPEUTICS, INC.
9812 Falls Road, Suite 114
Potomac, MD, 20854-3963

Information

DUNS: 072898005
# of Employees: 3

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09

    Amount: $222,900.00

    Not Available

    SBIRPhase I2014Department of Health and Human Services
  2. TAS::75 0849::TAS- SYNERGENE, INC SBIR PHASE II OPTION PERIOD

    Amount: $498,331.00

    SBIR Phase II to develop a LYOPHILLIZED form of Optimized scL-gad-d complex

    SBIRPhase I2011Department of Health and Human Services
  3. A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging

    Amount: $478,857.00

    DESCRIPTION (provided by applicant): The low rate of cure of pancreatic carcinoma is an important health problem. The American Cancer Society estimates that 32,000 Americans will be diagnosed with car ...

    STTRPhase I2006Department of Health and Human Services
  4. A Dual Molecular/Tumor Targeting Therapy for PanCa

    Amount: $1,159,666.00

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic cancer (PanCa). Over 90% of these will die of the disease making PanCa ...

    STTRPhase II2004Department of Health and Human Services
  5. Enhancement of Tumor-Targeted Transgene Expression

    Amount: $201,742.00

    DESCRIPTION (provided by applicant): In this application, the long-term goal is the development of an effective tumor-targeting lipoplex for systemic treatment of pancreatic cancer (PanCa), which has ...

    STTRPhase I2004Department of Health and Human Services
  6. A Dual Molecular/Targeting Therapy for PanCa

    Amount: $158,980.00

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one ...

    STTRPhase I2003Department of Health and Human Services
  7. TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY

    Amount: $138,762.00

    Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that ca ...

    STTRPhase I2002Department of Health and Human Services
  8. IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $634,660.00

    DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...

    STTRPhase II2002Department of Health and Human Services
  9. IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $0.00

    DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...

    STTRPhase I2002Department of Health and Human Services
  10. IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $138,625.00

    N/A

    STTRPhase I1999Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government